Prostate-specific antigen (PSA) screening for prostate cancer could cut the number of unnecessary biopsies if used as part of a new risk assessment, a study has found. Researchers from the European Randomised Study of Screening for Prostate Cancer (ERSPC) retrospectively analysed data from the ...
Please Login to read the full article.
